Voxelotor Brain Oxygenation and Neurocognitive Study

An Open Label, Single Arm, Multicenter Study to Evaluate the Effect of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Adolescents and Adults With Sickle Cell Disease

This is an open label, single arm multicenter trial to evaluate the effect of voxelotor treatment on cerebral blood flow (CBF) and neurocognitive function in adolescent and young adult participants (12-30 years of age) with sickle cell disease (SCD).

Study Overview

• Status: Withdrawn
• Conditions: Sickle Cell Disease
• Intervention / Treatment: Drug: Voxelotor Oral Tablet

Detailed Description

Eligible participants will receive daily treatment with 1500 mg voxelotor for 24 weeks. During screening, at 12 and 24 weeks, participants will undergo an MRI for evaluation of cerebral blood flow and oxygen extraction fraction as well as NIH toolbox testing for evaluation of executive function, processing speed, and nonexecutive function.

• Study Type: Interventional
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • New York
    • Bronx, New York, United States, 10467
      • The Children's Hospital at Montefiore

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 30 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female participants with confirmed diagnosis of SCD with HbSS or Hbβ0 thalassemia genotype. Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing during Screening.
2. Aged 12 to 30 years.
3. Screening Hb level ≥ 5.5 and ≤ 10.5 g/dL.
4. Must meet site-specific compliance requirements for a diagnostic MRI scan.
5. Able to answer NIH Toolbox Module questions in English
6. If participant is receiving hydroxyurea (HU) they must have been on a stable dose for at least 90 days prior to signing the ICF/AF, with no dose modifications or initiation of HU planned or anticipated by the Investigator.
7. If participant is receiving erythropoiesis-stimulating agents (ESAs) they must have been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator.
8. Participants, who if female and of child-bearing potential, agree to use highly effective methods of contraception from study start to 30 days after the last dose of study drug and who if male, agree to use barrier methods of contraception and refrain from donating sperm from study start to 30 days after the last dose of study drug.
9. Females of child-bearing potential must have a negative pregnancy test before the administration of study drug.
10. Written informed consent (≥ 18 years) or parental/guardian consent and participant assent (≥ 12-17 years) per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines.
11. Capable of complying with the requirements and restrictions in the protocol, and willing to participate in the study.

Exclusion Criteria:

1. History of overt stroke including hemorrhagic stroke, transient ischemic attacks, or spinal cord injury.
2. Grade 4 vasculopathy defined as moderate stenosis (50% to 69%) in more than 2 major cerebral arteries or severe stenosis (> 70%) in any major cerebral artery.
3. Non-MRI compatible metal hardware and/or metal braces.
4. Congenital brain malformation, previously diagnosed severe developmental disability (eg autism and/or intelligence quotient [IQ] <60, and/or severe attention deficit hyperactivity disorder [ADHD]), or impairment that would prevent the use of a computer tablet.
5. Participant is taking or has received voxelotor (Oxbryta®) within 90 days prior to the Screening Visit.
6. Participant is taking or has received crizanlizumab (Adakveo®) within 90 days prior to the Screening Visit.
7. Vaso-occlusive event requiring intravenous opioids within 28 days prior to Day 1.
8. Red blood cell (RBC) transfusion within 3 months before initiation of study drug or receives scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion).
9. Surgery within 8 weeks before Day 1 or planned elective surgery during the study.
10. Anemia due to bone marrow failure (eg, myelodysplasia).
11. Absolute reticulocyte count (ARC) < 100 × 10^9/L.
12. Screening alanine aminotransferase or aspartate aminotransferase > 4× upper limit of normal (ULN).
13. Severe renal dysfunction (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m^2) or on chronic dialysis.

14. Clinically significant bacterial, fungal, parasitic, or viral infection which requires therapy

    1. Acute bacterial infection requiring antibiotic use should delay Screening/enrollment until the course of antibiotic therapy has been completed.
    2. Known active hepatitis A, B, or C or are known to be human immunodeficiency virus (HIV) positive.
15. Symptomatic coronavirus disease of 2019 (COVID-19) infection.
16. Females who are breast-feeding or pregnant.
17. History of hematopoietic stem cell transplant or gene therapy.
18. Participants taking concomitant medications such as sensitive CYP3A4 substrates with a narrow therapeutic range, or strong CYP3A4 inducers.
19. Participated in another clinical trial of an investigational product (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational product (or medical device).
20. Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or render the participant unable/unlikely to comply with the study procedures (particularly the MRI scan).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active Drug; Generic Name: Voxelotor Dosage Form: tablet Dosage: 1500mg Frequency: QD Duration: 24 weeks	Drug: Voxelotor Oral Tablet; During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment; Other Names: Oxbryta

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in CBF	Change from Baseline in CBF through Week 24 measured by magnetic resonance imaging (MRI) using pseudo-continuous arterial spin labeling (pCASL).	Baseline to Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in executive functioning.	Change from Baseline through Week 24 in the executive cognitive abilities composite score (using Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Test) as assessed by the National Institutes of Health Toolbox Cognition Module.	Baseline to Week 24
Change in processing speed	Change from Baseline through Week 24 in processing speed (using Pattern Comparison Test) as assessed by the NIH Toolbox Cognition Module	Baseline to Week 24
Change in nonexecutive functioning	Change from Baseline through Week 24 in nonexecutive cognitive abilities composite score (using Picture Vocabulary Test, Oral Reading Recognition Test, and Picture Sequence Memory Test) as assessed by the NIH Toolbox Cognition Module.	Baseline to Week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Hb and hemolysis over time	Change and percent change from Baseline through Week 24 in hemolysis measures, including unconjugated bilirubin, absolute reticulocyte, % reticulocytes, and lactate dehydrogenase (LDH).	Baseline to week 24
Change in cerebral dynamics	Change from baseline through Week 24 in cerebral blood flow, oxygen extraction, and oxygen metabolism as measured by diffusion correlation spectroscopy (DCS)/frequency domain near infrared spectroscopy (FDNIRS) (if available) Correlation of cerebral hemodynamics measured by DCS/FDNIRS (if available) and cerebral hemodynamics measured by MRI.	Baseline to week 24
Change in global OEF as measured using T2-Relaxation-Under-Spin-Tagging (TRUST)	Change from Baseline to Week 24 in global OEF as measured using TRUST (if available)).	Baseline to week 24
Change in regional CBF within the grey matter	Change from Baseline through Week 24 in regional CBF within the grey matter.	Baseline to Week 24
Change in regional CBF within the white matter	Change in HRQOL scores using: Change from Baseline through Week 24 in regional CBF within the white matter	Baseline to Week 24
Change in regional OEF as measured using ASE (If available)	Change from Baseline to Week 24 in regional OEF as measured using ASE (if available)	Baseline to week 24
Correlation between changes from Baseline in CBF (MRI and DCS/FDNIRS)	Correlation between changes from Baseline in CBF (MRI and DCS/FDNIRS) and changes from Baseline in Hb levels	Baseline to Week 24
Correlation of changes from Baseline in OEF (MRI and DCS/FDNIRS)	Correlation of changes from Baseline in OEF (MRI and DCS/FDNIRS) and changes from Baseline in Hb levels	Baseline to Week 24
Correlation of change from Baseline in Hb	Correlation of change from Baseline in Hb and change from Baseline in executive abilities composite score	Baseline to Week 24
Change in HRQOL scores	Change in HRQOL scores using Patient Global Impression of Severity (PGI-S)	Baseline to Week 24
Change in HRQOL scores using Clinician Global Impression of Severity.	Change in HRQOL scores using Clinician Global Impression of Severity (CGI-S)	Baseline to Week 24
Incidence and severity of treatment-emergent AEs (TEAEs)	Incidence and severity of treatment-emergent AEs (TEAEs) baseline through week 24.	Baseline to Week 24

Collaborators and Investigators

• Sponsor: Pfizer
• Investigators: Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): August 9, 2023
• Primary Completion (Actual): August 23, 2023
• Study Completion (Actual): August 23, 2023

Study Registration Dates

• First Submitted: January 10, 2022
• First Submitted That Met QC Criteria: January 27, 2022
• First Posted (Actual): February 8, 2022

Study Record Updates

• Last Update Posted (Actual): August 9, 2024
• Last Update Submitted That Met QC Criteria: August 7, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Genetic Diseases, Inborn; Anemia; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Hemoglobinopathies; Anemia, Sickle Cell
• Other Study ID Numbers: GBT440-043; C5341027 (Other Identifier: Alias Study Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No